Score Your Stock

US stock · figures in US dollars · scored on full-year results

Gilead Sciences Gilead Sciences, Inc.

GILD · Healthcare · Drug Manufacturers - General
Bottom 4% of scored stocks
WeakBottom 4% of scored stocks
Weak SpotRecent Loss

Gilead Sciences scores 31/100 on fundamentals: in the bottom 4% of 503 scored S&P 500 stocks. Its strongest area is Cash & Dividends (63/100); its weakest is Price Fairness (0/100). It carries 2 warning flags: Weak Spot, Recent Loss.

Best
Cash 63
Weakest
Price 0
  • Carries a Weak Spot flag
  • Carries a Recent Loss flag

A financially stretched, expensively priced stock, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 213.1b#53 of 503 in the S&P 500EPSUS$ -2.65P/En/m (loss-making)P/B17.9×✗ vs sector median 3.7×Div yield2%✓ Top 38% in the S&P 50052w range · 94% of range114.02175.65
as of 31 Oct 2026

Nearby peers

Ranks #58 of 60 in Healthcare by score

#1Universal Health Services79#56Henry Schein35#57Becton Dickinson31
#58Gilead Sciences31
#59Charles River Laboratories24#60Moderna21

One-Minute Summary

Why Gilead Sciences scores 31

A financially stretched, expensively priced stock, but price fairness needs attention.

What looks good
What to watch

Business Strength

10
Why 10?
Pillar score: (0 + 1 + 0 + 0 + 0) = 1 of 10 points → 10
Return on Equity (ROE)-33%Weak4-Year Revenue Growth+5%/yrOkay4-Year Profit Growthn/m (loss-making)WeakNet Profit Marginn/m (loss-making)WeakQuarterly Momentumn/m (loss-making)Weak
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↓ -168.2%Equity ↓ -48.2%ROE % -32.7%
Net ProfitEquityROE %
5.7b480m8.5b-3.9b22.8b19.3b22.7b11.8b202320242025TTM24.8%2.5%37.5%-32.7%

Revenue & Net Profit, with Net Margin

Revenue ↑ +14.3%Net Profit ↓ -168.2%Net Margin % -12.5%
RevenueNet ProfitNet Margin %
27.1b28.8b29.4b31.0b5.7b480m8.5b-3.9b202320242025TTM20.9%1.7%28.9%-12.5%

Sales grew about 14.3% over 4 years: customers keep spending more with this company.

The company lost money in recent years: the bars below zero are losses, not profits.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +3.4%Net Profit ↓ -937.7%Net Margin % -134.5%
RevenueNet ProfitNet Margin %
7.5b7.6b6.7b7.1b7.8b7.9b7.0b7.8b1.3b1.8b1.3b2.0b3.1b2.2b2.0b-10.5bQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'2616.6%23.6%19.7%27.7%39.3%27.5%29%-134.5%
▼▲▲▲▲▲▲▼

Sales have stayed roughly flat over the last 8 quarters.

The company made a loss in at least one of the last 8 quarters: the bars below zero are losses, not profits.

Why 17?
Pillar score: (0 + 1 + 0) = 1 of 6 points → 17
Debt-to-Equity2.2×WeakCurrent Ratio1.3×OkayInterest Coverage-1.5×Weak
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt ↑ +5%Equity ↓ -48.2%D/E 2.2×
Total DebtEquityD/E
25.0b26.7b24.9b26.2b22.8b19.3b22.7b11.8b202320242025TTM1.1×1.4×1.1×2.2×

Borrowings have stayed roughly level: manageable, as long as profits stay healthy.

Short-term assets vs bills, with Current Ratio

Current Assets ↓ -13.3%Current Liabilities → -2.3%Current Ratio 1.3×
Current AssetsCurrent LiabilitiesCurrent Ratio
16.1b19.2b18.3b13.9b11.3b12.0b11.8b11.0b202320242025TTM1.4×1.6×1.6×1.3×
Why 63?
Pillar score: (0 + 2 + 2 + 1) = 5 of 8 points → 63
Dividend Quality2%Weak
Payout ratio: -105%
Operating Cash FlowPositive & growingStrongFree Cash FlowPositive & growingStrongCash & Cash EquivalentsPartly healthyOkay
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↑ +80.9%Free CF ↑ +86.9%
Operating CFFree CF
8.0b10.8b10.0b14.5b7.4b10.3b9.5b13.9b202320242025TTM

The business generates real cash, and more of it each year: a very healthy sign.

Cash vs Total Debt

Cash ↓ -47.8%Short-Term Debt ↑ +34.3%Total Debt ↑ +5%
CashShort-Term DebtTotal Debt
6.1b10.0b7.6b3.2b1.8b1.8b2.8b2.4b25.0b26.7b24.9b26.2b202320242025TTM

Dividends per Share, with Yield

DPS (cents) ↑ +8.2%Yield % 1.9%
DPS (cents)Yield %
7373737575777779797929230030831620222023202420255%4.2%4.2%1.9%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 0?
Pillar score: (0 + 0 + 0) = 0 of 6 points → 0
P/E Ration/m (loss-making)WeakP/B Ratio17.9×WeakPEG Ration/m (growth not measurable)Weak
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 170.68US$ 143.33US$ 115.97Oct '25Feb '26Jun '26Oct '26

The share price is up about 46% over the past year.

Why 58?
Pillar score: (0 + 1 + 2 + 2 + 2 + 0) = 7 of 12 points → 58
Earnings ConsistencyVery bumpyWeakDebt Trend (4yr)StableOkayShare Count Trend (4yr)-0%/yrStrongInventory vs Sales (4yr)-1.5 pp/yr vs salesStrongAsset Turnover Trend (4yr)+43.8%StrongQuarterly ConsistencyLoss in 1 of 8 quartersWeak
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +14.3%Inventory ↑ +9.3%Inv. % of Rev. 6.3%
RevenueInventoryInv. % of Rev.
27.1b28.8b29.4b31.0b1.8b1.7b1.8b2.0b202320242025TTM6.6%5.9%6%6.3%
Ranks #58 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#56Henry Schein35#57Becton Dickinson31
#58Gilead Sciences (you)31
#59Charles River Laboratories24#60Moderna21

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDividend Payout RatioDiv yieldP/E RatioP/B RatioPEG Ratio
2026US$ 31.0bUS$ -3.9bUS$ 14.5bUS$ 13.9bUS$ -609.0mUS$ 3.2bUS$ 26.2bUS$ 2.4bUS$ 11.8bUS$ 13.9bUS$ 11.0bUS$ 49.4bUS$ 37.6bUS$ 2.0b--33%-12%2.2×1.3×-1.5×-105%----
2025US$ 29.4bUS$ 8.5bUS$ 10.0bUS$ 9.5bUS$ -563.0mUS$ 7.6bUS$ 24.9bUS$ 2.8bUS$ 22.7bUS$ 18.3bUS$ 11.8bUS$ 59.0bUS$ 36.4bUS$ 1.8bUS$ 316.0m37%29%1.1×1.6×10.6×47%3%17.4×6.5×0.8
2024US$ 28.8bUS$ 480.0mUS$ 10.8bUS$ 10.3bUS$ -523.0mUS$ 10.0bUS$ 26.7bUS$ 1.8bUS$ 19.3bUS$ 19.2bUS$ 12.0bUS$ 59.0bUS$ 39.7bUS$ 1.7bUS$ 308.0m2%2%1.4×1.6×1.7×816%4%226.8×5.6×-
2023US$ 27.1bUS$ 5.7bUS$ 8.0bUS$ 7.4bUS$ -585.0mUS$ 6.1bUS$ 25.0bUS$ 1.8bUS$ 22.8bUS$ 16.1bUS$ 11.3bUS$ 62.1bUS$ 39.4bUS$ 1.8bUS$ 300.0m25%21%1.1×1.4×8.3×67%4%16.4×4.1×0.7